Seeking Alpha

In contrast to Clovis' share-price collapse, Celgene (CELG) is +8.6% after saying on Friday that...

In contrast to Clovis' share-price collapse, Celgene (CELG) is +8.6% after saying on Friday that its Abraxane treatment for advanced pancreatic cancer lengthened the survival of patients in a Phase III study. Pancreatic cancer could add up to $1B in sales of Abraxane, which is already approved to treat breast and lung tumors.
Comments (1)
  • TruffelPig
    , contributor
    Comments (4060) | Send Message
     
    Great news for patients of this terrible disease. There were many anekdotal rumors on cancer web sites on the efficiency of Abraxene in pancreatic cancer. The mechanism involves targeted delivery and thus the compatibility of the drug is much better than of the taxol.
    12 Nov 2012, 08:54 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|